Roivant Sciences Ltd. (NASDAQ:ROIV – Get Free Report) has been given an average rating of “Moderate Buy” by the ten ratings firms that are covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a hold rating and nine have given a buy rating to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $16.90.
Several equities analysts recently commented on the stock. Wolfe Research assumed coverage on shares of Roivant Sciences in a research report on Thursday, February 15th. They issued an “outperform” rating and a $17.00 price objective for the company. The Goldman Sachs Group raised their price target on shares of Roivant Sciences from $16.00 to $18.00 and gave the stock a “buy” rating in a research report on Wednesday, April 3rd. TheStreet raised shares of Roivant Sciences from a “d” rating to a “c+” rating in a research report on Tuesday, February 13th. HC Wainwright reissued a “buy” rating and set a $18.00 price target on shares of Roivant Sciences in a research report on Monday, April 22nd. Finally, Truist Financial reissued a “buy” rating and set a $23.00 price target on shares of Roivant Sciences in a research report on Monday, March 25th.
View Our Latest Stock Report on Roivant Sciences
Insider Activity at Roivant Sciences
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ROIV. GSA Capital Partners LLP purchased a new position in shares of Roivant Sciences during the 1st quarter worth $527,000. Mutual of America Capital Management LLC raised its holdings in shares of Roivant Sciences by 116.8% during the 1st quarter. Mutual of America Capital Management LLC now owns 325,937 shares of the company’s stock worth $3,435,000 after acquiring an additional 175,574 shares during the period. Fifth Lane Capital LP purchased a new position in shares of Roivant Sciences during the 1st quarter worth $211,000. Nordea Investment Management AB purchased a new position in shares of Roivant Sciences during the 1st quarter worth $2,851,000. Finally, Hussman Strategic Advisors Inc. purchased a new position in shares of Roivant Sciences during the 1st quarter worth $1,107,000. Hedge funds and other institutional investors own 64.76% of the company’s stock.
Roivant Sciences Stock Up 1.3 %
Shares of Roivant Sciences stock opened at $11.39 on Friday. The company has a debt-to-equity ratio of 0.06, a current ratio of 27.79 and a quick ratio of 27.79. Roivant Sciences has a 1 year low of $8.06 and a 1 year high of $13.24. The firm’s 50-day moving average is $10.89 and its two-hundred day moving average is $10.40. The stock has a market cap of $9.18 billion, a price-to-earnings ratio of 2.19 and a beta of 1.30.
Roivant Sciences (NASDAQ:ROIV – Get Free Report) last released its quarterly earnings results on Tuesday, February 13th. The company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.33) by $0.07. The business had revenue of $37.14 million during the quarter, compared to analyst estimates of $30.72 million. Roivant Sciences had a net margin of 3,624.14% and a negative return on equity of 33.38%. As a group, research analysts expect that Roivant Sciences will post -1.36 earnings per share for the current fiscal year.
Roivant Sciences Company Profile
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.
Read More
- Five stocks we like better than Roivant Sciences
- How to Invest in the FAANG Stocks
- MarketBeat Week in Review – 4/29 – 5/3
- What is the Dogs of the Dow Strategy? Overview and Examples
- Apple’s Earnings Show Investors Its Strength and Its Weakness
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- Bargain Alert: 3 Large Caps With Extremely Oversold RSIs
Receive News & Ratings for Roivant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roivant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.